Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target
The Pharma Data
JANUARY 4, 2021
Barber’s work will give Kiromic a significant acceleration in the clinical development of its therapy platform and an even more significant advantage over its competitors. Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. “We believe Prof.
40 
Let's personalize your content